Keyphrases
Chronic Heart Failure
100%
Agonist Treatment
100%
Diastolic Dysfunction
100%
First-in-man Trial
100%
Diastolic Function
100%
Adrenoceptor Agonist
100%
Failure Impact
100%
Placebo
75%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
50%
Between-group
50%
Echocardiography
50%
Reduced Ejection Fraction
50%
Cardiac Computed Tomography
50%
Mirabegron
50%
Ischemic Heart Disease
25%
Heart Failure
25%
Left Ventricular Ejection Fraction
25%
Ca2+
25%
Sodium
25%
Group by
25%
Na +
25%
Follow-up Data
25%
Double-blind Trial
25%
Previous Literature
25%
Heart Failure Therapy
25%
Adrenoceptors
25%
First-in-man
25%
Cytosolic Calcium
25%
Clinically Significant Change
25%
New York Heart Association
25%
Left Atrial Volume Index
25%
β3-adrenoceptor
25%
Organ Congestion
25%
Sodium-calcium Exchanger
25%
Sodium Gradient
25%
Calcium Efflux
25%
Medicine and Dentistry
Heart Failure
100%
Diastolic Dysfunction
100%
Diastolic Function
100%
Sympathomimetic Drug
100%
Placebo
75%
Amino Terminal Sequence
50%
Natriuretic Factor
50%
Isotopes of Calcium
50%
Echocardiography
50%
Ejection Fraction
50%
Cardiac Computed Tomography
50%
Mirabegron
50%
Biological Marker
25%
Heart Left Ventricle Ejection Fraction
25%
Ischemic Heart Disease
25%
Adrenergic Receptor
25%
Sodium Ion
25%
Calcium Transport
25%
Sodium Calcium Exchange Protein
25%
Beta 3 Adrenergic Receptor Stimulating Agent
25%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Diastolic Dysfunction
100%
Adrenergic Receptor Stimulating Agent
100%
Placebo
75%
Natriuretic Factor
50%
Mirabegron
50%
Ischemic Heart Disease
25%
Biological Marker
25%
Effusion
25%
Adrenergic Receptor
25%
Sodium Ion
25%
Sodium Calcium Exchange Protein
25%
Beta 3 Adrenergic Receptor Stimulating Agent
25%